INTRODUCTION
============

Acne, a follicular disorder involving the specialized pilosebaceous units in the skin, is one of the most common skin disorders treated by dermatologists. The major factors involved in the pathophysiology of acne are obstruction of follicles due to abnormal keratinization of infundibular epithelium, stimulation of sebum secretion by androgensensitive sebaceous glands, and inflammation induced by microbial colonization with *Propionibacterium acnes*[@B1].

Systemic antibiotics have been the mainstay of treatment for moderate to severe acne vulgaris to date, and the effectiveness of several antibiotics, including oxytetracycline, minocycline, doxycycline and erythromycin, in treating acne has been established[@B2]. Although doxycycline is considered to be a first-line anti-acne antibiotic, it is known to have side effects, such as gastrointestinal symptoms, tooth discoloration, photosensitive reactions, pigmentation changes, and central nervous system effects[@B3]. Moreover, doxycycline has many contraindications and drug interactions. For example, it cannot be used during pregnancy or in children under 12 years of age. In addition, the use of doxycycline with isotretinoin, another effective agent in acne treatment, should be avoided because of the increased risk of benign intracranial hypertension[@B4]. Some authors have emphasized the efficacy of oral azithromycin pulse therapy in acne treatment[@B5][@B6].

Azithromycin is an orally administered macrolide antimicrobial drug, structurally related to erythromycin, with an expanded spectrum of activity and improved pharmacokinetic features. Azithromycin is characterized by rapid uptake from the circulation, followed by slow release. The long elimination half-life from tissue permits less-frequent administration[@B7]. As acne runs a variable course with fluctuations, long-term therapy is often needed. Therefore, drugs with relatively long half-lives such as azithromycin can be useful in increasing patient compliance. In addition, azithromycin can be employed in combination with isotretinoin and can be used during pregnancy and childhood. The adverse effects of azithromycin are limited mainly to mild gastrointestinal discomfort and occur less frequently than with other antibiotics. However, few clinical studies have directly compared oral azithromycin pulse therapy with oral daily doxycycline in the management of acne. Therefore, we conducted a meta-analysis with the aim of comparing the efficacy of oral azithromycin pulse therapy with that of oral daily doxycycline in acne treatment using multiple randomized controlled trials (RCTs).

MATERIALS AND METHODS
=====================

This study followed the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (Moher et al.[@B8], 2009) ([Supplement 1](#S1){ref-type="supplementary-material"}).

Search strategy
---------------

A search was conducted of five scientific databases (MEDLINE, EMBASE, Cochrane Library, SCOPUS, and Web of Science) to identify studies in the literature that compared oral azithromycin pulse therapy with oral daily doxycycline in the management of acne. We searched MEDLINE (January 1, 1964 to December 4, 2016), EMBASE (January 1, 1947 to December 4, 2016), and Cochrane Library (January 1, 1966 to December 4, 2016) with no restriction on language or publication year. The following keywords and medical subject headings were used for the MEDLINE search: "acne vulgaris," "azithromycin," and "doxycycline." The search strategies were developed using indices of the various databases based on the MEDLINE strategy ([Supplement 2](#S2){ref-type="supplementary-material"}). In addition to the initial electronic search, manual searching for additional relevant publications was performed.

Study selection
---------------

Two reviewers independently selected studies based on the following predefined inclusion criteria: 1) moderate or severe acne vulgaris diagnosed clinically or using validated diagnostic criteria; 2) comparison of the clinical outcomes of oral azithromycin pulse therapy and oral doxycycline daily therapy in moderate or severe acne vulgaris; 3) use of clinical outcomes, including the remaining acne lesion count and/or patients\' self-assessment of treatment and/or investigators\' assessment of lesions at the end of treatment, to evaluate efficacy; 4) maintenance of treatment for at least 3 months; 5) RCT design; and 6) availability of a full-text article. The two reviewers screened titles and abstracts to exclude reviews, letters, commentaries, and case reports. When a study was described in more than one publication, only the most recent or complete article was used. A full list of the exclusion criteria can be found in [Fig. 1](#F1){ref-type="fig"}. Six studies were finally selected.

Data extraction
---------------

Two reviewers independently extracted data from the six studies using a predefined data extraction form. All disagreements were resolved by discussion. We extracted the following variables from the studies: 1) authors; 2) year of publication; 3) demographic characteristics of the study population (number, age); 4) inclusion criteria for moderate or severe acne vulgaris; 5) treatment protocol; 6) length of treatment; and 7) method of efficacy evaluation. The relevant clinical data were summarized separately according to the following outcomes: 1) remaining acne lesion count; 2) patients\' self-assessment of treatment; and 3) investigators\' assessment of treatment. We also evaluated safety outcomes by recording severe side effects that occurred during treatment in all included studies. We defined severe side effects as intolerable side effects that necessitated discontinuation of treatment.

Statistical analysis
--------------------

We planned to perform a meta-analysis to compare the efficacy of oral azithromycin pulse therapy with that of oral daily doxycycline in the management of moderate to severe acne vulgaris. To do so, the clinical treatment outcome was measured according to the following data: remaining acne lesion count, patients\' self-assessment of treatment, and investigators\' assessment of treatment. Three studies involved inflammatory acne lesion counts, two included non-inflammatory acne lesion counts, two involved patient self-assessment, and all six included the investigators\' assessment of treatment. These outcomes were pooled in this analysis. For remaining acne lesion counts, smaller numbers meant a better response to treatment. In evaluating the patient\'s self-assessment of treatment, favorable responses were defined as "excellent" and "good" ratings. In evaluating the investigators\' assessment of treatment, treatment responses were expressed as percentages or by quantitative lesion scores on a 4-point scale (−1, worsened; 0, unchanged; 1, improved; and 2, clear). We defined an excellent response as "a reduction of 75% or more" or "improved or clear state." Next, we defined a moderate response as "a reduction of 50% or more" or an "improved or clear state." We conducted pooled analyses using random-effects weighting for meta-analyses of the outcomes reported by multiple studies that were sufficiently similar to justify combining results. However, if the clinical heterogeneity was too great, studies were not pooled. For dichotomous outcomes, we calculated risk ratios using the Mantel-Haenszel method. For continuous outcomes, we used weighted mean differences (WMDs) and 95% confidence intervals (CIs) with the inverse variance method. Heterogeneity in all meta-analyses was measured using *I*^2^, which indicates the proportion of variation in effect estimates across trials that is due to heterogeneity, rather than sampling error. *I*^2^ values \>50% and *p*-values from the χ^2^ test \<0.10 were taken to indicate a statistically large degree of heterogeneity among the included studies. If substantial statistical heterogeneity was noted (I2\>50%), we planned to explore individual study characteristics and those of subgroups of the main body of evidence. We performed a sensitivity analysis according to the quality of individual studies and blinding of outcome assessment. All calculations were performed using Review Manager ver. 5.2 (The Cochrane Collaboration, Oxford, UK). This study is based on Cochrane Review Methods.

Assessment of risk of bias
--------------------------

The Cochrane Collaboration\'s risk of bias tool was used to assess the risk of bias in all included studies. The following items were assessed and recorded: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective reporting (reporting bias). Each of the included studies was rated as having low, unclear, or high bias based on these items ([Supplement 3](#S3){ref-type="supplementary-material"}).

RESULTS
=======

Identification of studies
-------------------------

The database search yielded 1,341 articles, of which 1,331 were excluded because the titles and abstracts indicated that they did not fulfill the selection criteria; an additional article was excluded because the full text was not available. We obtained the full text of the remaining nine articles. We subsequently identified six relevant studies after excluding three (two had no control group, and one did not provide enough data; [Fig. 1](#F1){ref-type="fig"}). Ultimately, six studies were included in the meta-analysis.

Study characteristics and patients
----------------------------------

Of the six studies, two were performed in Iran and one each was performed in India, Turkey, Poland, and Pakistan. The main characteristics of the studies are shown in [Table 1](#T1){ref-type="table"}. The six studies enrolled a total of 906 patients with moderate or severe acne vulgaris. Overall, 452 patients were assigned randomly to the azithromycin pulse therapy group, and the remaining 454 patients were assigned to the daily doxycycline therapy group. Patients assigned to the azithromycin pulse therapy group took 500 mg of azithromycin 1\~3 times weekly or 4 times monthly. Patients in the daily doxycycline group took 100 mg of doxycycline once or twice daily.

Studies defined "moderate acne vulgaris" by using specific tools or by measuring clinical findings. In one study, "moderate acne vulgaris" was defined according to Burke and Cunliffe\'s Leeds technique[@B9][@B10]; in another, recommendations from the Consensus Conference on Acne Classification were used[@B11][@B12]. In two studies, "moderate acne vulgaris" was diagnosed by counting inflammatory acne lesions and patients with at least 10 lesions were included[@B13][@B14]. In two other studies, "moderate acne vulgaris" was defined based on clinical findings[@B15][@B16].

Inflammatory acne lesions were counted in three of the six studies. Of these[@B13][@B14][@B15], non-inflammatory lesions (comedones) were also counted in two studies[@B13][@B14]. Two studies included patients\' assessments of their treatment[@B13][@B14], with improvement measured on a scale of 0\~5 (0, worsening; 1, no change; 2, mild improvement; 3, moderate improvement; 4, good improvement; and 5, excellent improvement). Favorable patient responses were defined as "excellent" and "good" ratings. Investigators evaluated the response to treatment in all studies. Treatment responses were expressed as percentages in five studies[@B12][@B13][@B14][@B15][@B16] and by quantitative lesion scores on a 4-point scale (−1, worsened; 0, unchanged; 1, improved; and 2, clear) in one study[@B10]. We defined a meaningful response as a score of 2. Initially, we defined an excellent response as "a reduction of 80% or more" in four studies[@B12][@B13][@B14][@B16], "a reduction of 75% or more" in one study[@B15], and an "improved or clear state" in one study[@B10]. Next, we defined a moderate response as "a reduction of 50% or more" in five studies[@B12][@B13][@B14][@B15][@B16] and an "improved or clear state" in one study[@B10]. Each response was then analyzed individually.

Clinical treatment outcome measures
-----------------------------------

At 12 weeks, remaining inflammatory and non-inflammatory acne lesion profiles were similar in the azithromycin pulse therapy and doxycycline daily therapy groups, with no significant difference between groups and no heterogeneity (WMD, 0.66; 95% CI, −0.50\~1.82; *I*^2^=10%; [Fig. 2A](#F2){ref-type="fig"}). The meta-analysis of patients\' self-assessment data from two studies revealed no significant difference between groups and moderate heterogeneity (relative risk \[RR\], 0.91; 95% CI, 0.58\~1.42; *I*^2^=64%; [Fig. 2B](#F2){ref-type="fig"}). Also, we conducted a meta-analysis of investigators\' assessment of treatment in all six studies. Again, the analysis showed no significant difference between groups in both excellent and moderate response (excellent response: RR, 0.84; 95% CI, 0.60\~1.19; *I*^2^=90%; moderate response: RR, 0.98; 95% CI, 0.93\~1.02; *I*^2^=46%; [Fig. 2C](#F2){ref-type="fig"}). The assessment outcomes are shown in [Fig. 2](#F2){ref-type="fig"}.

Sensitivity analysis outcomes
-----------------------------

We conducted a sensitivity analysis of remaining inflammatory acne lesion counts and investigators\' assessment of treatment according to the quality of individual studies and blinding of outcome assessment. The sensitivity analysis outcomes are shown in [Fig. 3](#F3){ref-type="fig"}. The sensitivity analysis changed the direction of clinical outcomes, although it was not statistically significant. At 12 weeks, the remaining inflammatory acne lesion counts were similar in the azithromycin pulse therapy and doxycycline daily therapy groups, with no significant difference between groups (WMD, 0.83; 95% CI, −1.15\~2.81; [Fig 2A](#F2){ref-type="fig"}). Among them, two studies were assumed to have a low risk of bias and the other was a sponsored study. The individual sensitivity analysis outcomes showed the direction change (low risk of bias: WMD, 0.04; 95% CI, −1.06\~1.15; sponsored study: WMD, 3.00; 95% CI, 0.36\~5.64; [Fig. 3A](#F3){ref-type="fig"}). Similarly, we performed a sensitivity analysis about the investigators\' assessment of treatment. The meta-analysis of the six included studies showed no significant difference between groups (excellent response: RR, 0.84; 95% CI, 0.60\~1.19; [Fig. 2C](#F2){ref-type="fig"}). Among them, two studies were assumed to have a low risk of bias, three studies had a high risk of bias, and the other one was a sponsored study. The individual sensitivity analysis outcomes showed the direction change (low risk of bias: RR, 1.12; 95% CI, 0.84\~1.50; high risk of bias: RR, 0.71; 95% CI, 0.35\~1.43; sponsored study: RR, 0.87; 95% CI, 0.69\~1.10; [Fig. 3B](#F3){ref-type="fig"}).

Safety outcomes
---------------

We reviewed all side effects reported in the six studies. In general, the side effects were mild and transient, and did not require the discontinuation of therapy. For example, side effects included mild epigastric pain, diarrhea, vomiting, abdominal pain, constipation, malaise, and mild headache. However, some patients experienced intolerable side effects and subsequently discontinued therapy. Severe side effects are shown in [Table 2](#T2){ref-type="table"}. Severe side effects were defined as intolerable side effects that necessitated the discontinuation of treatment and included severe gastrointestinal discomfort, photosensitivity, vaginitis, and severe vertigo. Although a statistical analysis of these side effects was not performed, the incidence of severe adverse events was higher in the doxycycline daily therapy group than in the azithromycin pulse therapy group.

DISCUSSION
==========

The results of our meta-analysis show that doxycycline daily therapy and azithromycin pulse therapy had similar efficacy in the treatment of moderate to severe acne vulgaris at 12 weeks, with no significant difference between groups. The clinical outcome measures included the remaining acne lesion count, patients\' self-assessment of their treatment, and investigators\' assessment of the treatment. In regards to safety outcomes, the doxycycline daily therapy group reported more severe adverse events than the azithromycin pulse therapy group. Even though it was not statistically significant, the meta-analysis of clinical outcome measures was weighed toward the doxycycline daily therapy group. Therefore, we conducted a sensitivity analysis of the remaining inflammatory acne lesion counts and investigators\' assessment of treatment according to the quality of individual studies and blinding of outcome assessment. We chose these outcome measures for the sensitivity analysis because the blinding of outcome assessment can have a major influence on them. The sensitivity analysis changed the direction of the two clinical outcomes. Of the three studies[@B13][@B14][@B15] evaluated for remaining inflammatory acne lesion counts, one study[@B15] was a company-sponsored study and reported greater efficacy in the doxycycline daily therapy group. In contrast, two studies[@B13][@B14] that showed their blinding of outcome assessment clearly reported more favorable efficacy in the azithromycin pulse therapy group. Similarly, of the six studies[@B10][@B12][@B13][@B14][@B15][@B16] that evaluated the investigator\'s assessment of treatment, three studies[@B10][@B12][@B16] that did not show their blinding of outcome assessment clearly reported more favorable efficacy in the doxycycline daily therapy group. In contrast, two studies[@B13][@B14] that showed their blinding of outcome assessment clearly reported more favorable efficacy in the azithromycin pulse therapy group. The one company-sponsored study[@B15] showed more favorable efficacy in the doxycycline daily therapy group. Sometimes, company-sponsored studies are significantly more likely to paint a rosy picture of the drug being evaluated than independent trials. Two studies[@B12][@B16] did not report any side effects. Both of them reported more favorable efficacy in the doxycycline daily therapy group and were among the previous three studies that showed high detection bias. In light of this, there could also be reporting bias. Taken together, the high risk of blinding of outcome assessment of studies could have led to an overestimation of doxycycline efficacy in their assessment. Of all six studies, one study[@B16] was distinctively heterogeneous compared with the other five. It reported the most favorable efficacy of doxycycline daily therapy among all six studies. However, the study did not report any adverse events and also did not describe its blinding of outcome assessment. This could have created reporting bias and thus led to an overestimation of doxycycline efficacy.

Antibiotics are a well-known mainstream treatment for acne because of their anti-inflammatory and antimicrobial properties. Systemic antibiotics have been proven to reduce not only, inflammatory, but also non-inflammatory, lesions of acne. Research has also shown that once *P. acnes* colonization occurs, those organisms liberate free fatty acids that are comedogenic, and thus yield non-inflammatory lesions[@B17]. Among various antibiotics, tetracycline and its derivatives are used widely in the treatment of acne vulgaris. Doxycycline is often preferred to other tetracyclines due to its safer side effect profiles, and it is among the most commonly prescribed antibiotics in the management of acne. Despite its overall safety record, doxycycline has fatal disadvantages. Sometimes, its use must be limited because it is contraindicated in females of childbearing age and children under 12 years of age. Also, doxycycline has been reported to have several side effects. The most common adverse events associated with doxycycline are gastrointestinal, including heartburn, nausea, vomiting, diarrhea, gastritis, and esophagitis. The second most commonly reported side effect is photosensitivity. In addition, several serious doxycycline-induced adverse reactions, such as pseudotumor cerebri and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, have emerged over the last few years. Although discontinuation of the medication yielded improvement in most reported cases, a few patients suffered from a permanent loss of visual acuity or loss of visual field[@B18][@B19][@B20][@B21].

In the context of the fairly large number of adverse events related to tetracycline and its derivatives, some comparative clinical trials have shown that the tolerability profile of azithromycin is superior to that of tetracyclines[@B13][@B16][@B22]. Clinical isolates of *P. acnes* are highly susceptible to macrolide antibiotics. Although such antibiotics can effectively treat acne, they are not considered to be first-line drugs because of the risk of bacterial resistance[@B23]. Antibiotic resistance among *P. acnes* is increasing globally and may contribute significantly to treatment failure. Among the various macrolide antibiotics, *P. acnes* is more commonly resistant to erythromycin and clindamycin, and less so to azithromycin[@B24][@B25][@B26][@B27][@B28][@B29][@B30][@B31][@B32][@B33][@B34][@B35][@B36][@B37][@B38][@B39]. Moon et al.[@B33] examined the antibiotic resistance profile of microbial strains isolated from Korean acne patients and reported that higher proportions of *P. acnes* isolates were resistant to clindamycin (30%) and erythromycin (26.7%) than to azithromycin (6.7%) and doxycycline (6.7%).

Also, azithromycin affords many advantages compared with other antibiotics. In terms of pharmacokinetics, azithromycin is known to be more stable in gastric acid than are older generation macrolides, including erythromycin, and it achieves rapid uptake from the circulation with a high tissue concentration following oral administration. Moreover, azithromycin has a long half-life, enabling less-frequent administration and making it suitable for use as pulse therapy, which can improve patient compliance and the development of *P. acnes* resistance; the dose is low. Several studies[@B1][@B2][@B3] reported that pulse dosing was successful; however, no standard regimen is yet available[@B6][@B10][@B40]. Some studies[@B4][@B5] have compared the efficacies of different pulse-dosing protocols and found no significant among-protocol difference in efficacy [@B41][@B42]. Accordingly, although the treatment protocols differed slightly among included studies, we could not consider that this a major problem.

Furthermore, azithromycin is well tolerated and has a good safety record. Previously, Bakar et al.[@B43] reported that the side effects of azithromycin were minimal and well tolerated in most patients treated for papulopustular rosacea. Kashkouli et al.[@B44] also reported mild and temporary side effects, which did not require treatment, during treatment for meibomian gland dysfunction, whereas the doxycycline group had significantly more side effects. In the six studies included in the present meta-analysis, severe adverse events were detected more frequently in the doxycycline therapy group. Moreover, azithromycin has no major drug interaction. Of the anti-acne antibiotics used frequently, azithromycin is the most eligible for use in combination with isotretinoin. Previous studies showed that a combination of low-dose isotretinoin and oral azithromycin pulse therapy was effective in the treatment of severe acne. Combination therapy might yield synergistic effects and overcome the dose-dependent adverse effects of isotretinoin, as well as lower the incidence of relapse compared with monotherapy[@B45][@B46]. Azithromycin is not contraindicated in pregnancy, unlike tetracyclines; thus, it can be safely administered to women of childbearing age and to pregnant women with severe aggravated lesions, with no increased risk of congenital malformation or miscarriage[@B47]. Due to these advantages, azithromycin is expected to be a good alternative to conventional acne antibiotics. Many previous studies have demonstrated that azithromycin was effective in treating acne, with similar efficacy to that of doxycycline; our results are in line with these reports.

Our study has several limitations. First, only a small number of eligible studies were included. Second, detection and reporting biases may have been present. The inclusion of a greater number of high-quality RCTs is needed in future analyses.

In conclusion, the present work revealed significant evidence that azithromycin pulse therapy is a likely equivalent to daily doxycycline therapy in the management of moderate or severe acne vulgaris and may be a good alternative drug for patients who cannot tolerate tetracycline. In addition, reevaluation of the efficacy of azithromycin in treating acne would be helpful; azithromycin may be used widely with a better safety profile than other drugs, including doxycycline. To our knowledge, this is the first meta-analysis to compare the efficacy of oral azithromycin pulse therapy with that of oral daily doxycycline therapy in the treatment of acne vulgaris.
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Supplementary data can be found via <http://anndermatol.org/src/sm/ad-30-417-s001.pdf>.

###### Supplementary Table 1

PRISMA 2009 Checklist

###### Supplement 2

Search strategy on MEDLINE, EMBASE, Cochrane Library, SCOPUS, and Web of Science

###### Supplementary Fig. 1

Risk of bias assessment of the included studies.
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![Forest plot of the meta-analysis for clinical outcome measures. (A) Remaining acne lesion counts. (B) Patient\'s self-assessment of treatment. (C) Investigator\'s assessment of treatment. SD: standard deviation, IV: inverse variance, CI: confidence interval, df: degree of freedom, M-H: Mantel-Haenszel.](ad-30-417-g002){#F2}
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###### Characteristics of the six randomized controlled trials included in the final analysis

![](ad-30-417-i001)

  Study (year)                                                                                      No. of patient   Age (yr)     Treatments protocol   Methods of evaluating efficacies                                                                                                                                 
  ------------------------------------------------------------------------------------------------- ---------------- ------------ --------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------
  Parsad et al. (2001)[@B10]                                                                        30 (6.6)         30 (6.6)     ≥16                   Azithromycin 500 mg 4 d/mo+topical 0.05% tretinoin                           100 mg doxycycline once daily+topical 0.05% tretinoin cream                         1\. Investigator\'s assessment of treatment using a 4 point scale
  Kus et al. (2005)[@B13]                                                                           25 (5.5)         26 (5.7)     18\~30                Azithromycin 500 mg 3 d/wk (1st mo), 2 d/wk (2nd mo), once a week (3rd mo)   Doxycycline 100 mg twice a day (1st mo), once daily (2nd mo, 3rd mo)                1\. Facial inflammatory, non-inflammatory acne lesion counts
  2\. Patient\'s own assessment of treatment using a 5 point scale                                                                                                                                                                                                                                                       
  3\. Investigator\'s assessment of treatment (treatment responses were expressed as percentages)                                                                                                                                                                                                                        
  Babaeinejad et al. (2011)[@B12]                                                                   50 (11.1)        50 (11.0)    ≥13                   Azithromycin 500 mg 4 d/mo                                                   100 mg doxycycline once daily                                                       1\. Investigator\'s assessment of treatment (treatment responses were expressed as percentages)
  Maleszka et al. (2011)[@B15]                                                                      120 (26.5)       120 (26.4)   ≥14                   Azithromycin 500 mg 3 d/wk (1st wk), followed by 500 mg weekly               100 mg doxycycline twice a day (1st d), followed by 100 mg doxycycline once daily   1\. Facial inflammatory acne lesion counts
  2\. Investigator\'s assessment of treatment (treatment responses were expressed as percentages)                                                                                                                                                                                                                        
  Moravvej et al. (2012)[@B14]                                                                      34 (7.5)         35 (7.7)     18\~30                Azithromycin 500 mg 3 d/wk                                                   100 mg doxycycline daily                                                            1\. Facial inflammatory, non-inflammatory acne lesion counts
  2\. Patient\'s own assessment of treatment using a 5 point scale                                                                                                                                                                                                                                                       
  3\. Investigator\'s assessment of treatment (treatment responses were expressed as percentages)                                                                                                                                                                                                                        
  Ullah et al. (2014)[@B16]                                                                         193 (42.7)       193 (42.5)   14\~30                Azithromycin 500 mg 4 d/mo                                                   100 mg doxycycline daily                                                            1\. Investigator\'s assessment of treatment (treatment responses were expressed as percentages)

###### Serious adverse events leading to the discontinuation of therapy
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  Severe side effect          Doxycycline   Azithromycin
  --------------------------- ------------- --------------
  Severe diarrhea             0             4
  Severe nausea               2             0
  Severe epigastric pain      3             0
  Photosensitivity            3             0
  Vaginitis                   2             0
  Abnormal blood cell count   1             0
  Severe vertigo              1             0
